Trial Profile
A Study to Evaluate the Effects of Calcium Supplementation on the Efficacy and Safety of Recombinant Human Parathyroid Hormone (ALX1-11) in Postmenopausal Women With Osteoporosis (CAP Study)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Parathyroid hormone (Primary) ; Calcium supplements
- Indications Menopause; Postmenopausal osteoporosis
- Focus Therapeutic Use
- Acronyms CAP
- Sponsors NPS Pharmaceuticals
- 12 Aug 2008 Actual end date added (Apr 2005) as reported by ClinicalTrials.gov.
- 12 Aug 2008 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 08 Nov 2005 New trial record.